DefiniGEN has a unique platform technology for generating phenotypically validated human cell disease models for a range of rare metabolic and liver diseases, to optimize preclinical drug discovery.
The company has IP from the labs of Professor Ludovic Vallier at Cambridge University to generate terminally differentiated human cells of endodermal lineage from iPSC. We provide iPSC-derived hepatocytes, pancreatic cells, cholangiocytes and intestinal cells from healthy and diseased donors which closely resemble human primary cells. Off-the-shelf hepatocyte products include Alpha1-antitrypsin disorder, GSD1a, and familial hypercholesterolemia disease models. We also provide MODY3 and neonatal diabetes pancreatic cell models.
Babraham Research Campus
Cambridge, CB22 3AT United Kingdom